Advisory Committee on Immunization Practices (ACIP), 58843 [2012-23390]
Download as PDF
<![CDATA[
Federal Register / Vol. 77, No. 185 / Monday, September 24, 2012 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Committee on Immunization
Practices (ACIP)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting of the
aforementioned committee:
TKELLEY on DSK3SPTVN1PROD with NOTICES
Times and Dates
8 a.m.–6 p.m., October 24, 2012.
8 a.m.–4 p.m., October 25, 2012.
Place: Centers for Disease Control and
Prevention, Tom Harkin Global
Communications Center, 1600 Clifton
Road NE., Building 19, Kent ‘‘Oz’’
Nelson Auditorium, Atlanta, Georgia
30333.
Status: Open to the public, limited
only by the space available.
Purpose: The committee is charged
with advising the Director, CDC, on the
appropriate uses of immunizing agents.
In addition, under 42 U.S.C. 1396s, the
committee is mandated to establish and
periodically review and, as appropriate,
revise the list of vaccines for
administration to vaccine-eligible
children through the Vaccines for
Children (VFC) program, along with
schedules regarding the appropriate
periodicity, dosage, and
contraindications applicable to the
vaccines. Further, under provisions of
the Affordable Care Act, at section 2713
of the Public Health Service Act,
immunization recommendations of the
ACIP that have been adopted by the
Director of the Centers for Disease
Control and Prevention must be covered
by applicable health plans.
Matters To Be Discussed: The agenda
will include discussions on: 2013 adult
immunization schedule, 2013 child/
adolescent immunization schedule,
Japanese encephalitis, rotavirus, human
papillomavirus vaccines, hepatitis B
vaccine, meningococcal vaccines,
influenza, measles-mumps-rubella
vaccine, pertussis and vaccine supply.
Recommendation votes are scheduled
for pertussis vaccines, meningococcal
vaccines, measles-mumps-rubella
vaccine, hepatitis B vaccine, child/
adolescent immunization schedule, and
the adult immunization schedule. VFC
votes are scheduled for pertussis
vaccines, meningococcal vaccines, and
influenza vaccine. Time will be
available for public comment.
Agenda items are subject to change as
priorities dictate.
VerDate Mar<15>2010
18:54 Sep 21, 2012
Jkt 226001
Meeting is webcast live via the World
Wide Web; for instructions and more
information on ACIP please visit the
ACIP web site: https://www.cdc.gov/
vaccines/acip/.
Contact Person for More Information:
Stephanie B. Thomas, National Center
for Immunization and Respiratory
Diseases, CDC, 1600 Clifton Road NE.,
MS–A27, Atlanta, Georgia 30333,
telephone 404/639–8836; Email
ACIP@CDC.GOV.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: September 14, 2012.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2012–23390 Filed 9–21–12; 8:45 am]
BILLING CODE 4160–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30 Day–12–12IW]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
requests, call (404) 639–7570 or send an
email to omb@cdc.gov. Send written
comments to CDC Desk Officer, Office of
Management and Budget, Washington,
DC 20503 or by fax to (202) 395–5806.
Written comments should be received
within 30 days of this notice.
Proposed Project
Fetal Alcohol Spectrum Disorders
Regional Training Centers—New—
National Center on Birth Defects and
Developmental Disabilities (NCBDDD),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
This program will collect program
evaluation data from participants of
trainings for medical and allied health
students and practitioners regarding
fetal alcohol spectrum disorders
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
58843
(FASDs) conducted by the FASD
Regional Training Centers (RTCs)
through a cooperative agreement with
the CDC.
Prenatal exposure to alcohol is a
leading preventable cause of birth
defects and developmental disabilities.
The term fetal alcohol spectrum
disorders (FASDs) describes the full
continuum of effects that can occur in
an individual exposed to alcohol in
utero. These effects include physical,
mental, behavioral, and learning
disabilities. All of these effects have
lifelong implications.
Health care professionals play a
crucial role in identifying women at risk
for an alcohol-exposed pregnancy and
in identifying effects of prenatal alcohol
exposure in individuals. However,
despite the data regarding alcohol
consumption among women of
childbearing age and the estimated
prevalence of FASDs, screening for
alcohol use among female patients of
childbearing age and screening for
FASDs are not yet common standards of
care. In addition, it is known from
surveys of multiple provider types that
although they might be familiar with the
teratology and clinical presentation of
FASDs, they report feeling less prepared
to identify for referral or to diagnose a
child and even less prepared to manage
and coordinate the treatment of children
with FASDs. Similarly, among
obstetrician-gynecologists, although
almost all report asking their patients
about alcohol use during pregnancy, few
use a proper screening tool for alcohol
assessment.
There is a need for the training of
medical and allied health students and
practitioners in the prevention,
management, and identification of
FASDs, hence the recommendations
that have been put forward in this area.
As part of the fiscal year 2002
appropriations funding legislation, the
U.S. Congress mandated that the CDC,
acting through the NCBDDD Fetal
Alcohol Syndrome (FAS) Prevention
Team and in coordination with the
National Task Force on Fetal Alcohol
Syndrome and Fetal Alcohol Effect
(NTFFAS/FAE), other federally funded
FAS programs, and appropriate
nongovernmental organizations (NGOs),
would (1) develop guidelines for the
diagnosis of FAS and other negative
birth outcomes resulting from prenatal
exposure to alcohol; (2) incorporate
these guidelines into curricula for
medical and allied health students and
practitioners, and seek to have them
fully recognized by professional
organizations and accrediting boards;
and (3) disseminate curricula to and
provide training for medical and allied
E:\FR\FM\24SEN1.SGM
24SEN1
]]>Agencies
[Federal Register Volume 77, Number 185 (Monday, September 24, 2012)]
[Notices]
[Page 58843]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-23390]
[[Page 58843]]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Advisory Committee on Immunization Practices (ACIP)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the following meeting of the aforementioned
committee:
Times and Dates
8 a.m.-6 p.m., October 24, 2012.
8 a.m.-4 p.m., October 25, 2012.
Place: Centers for Disease Control and Prevention, Tom Harkin
Global Communications Center, 1600 Clifton Road NE., Building 19, Kent
``Oz'' Nelson Auditorium, Atlanta, Georgia 30333.
Status: Open to the public, limited only by the space available.
Purpose: The committee is charged with advising the Director, CDC,
on the appropriate uses of immunizing agents. In addition, under 42
U.S.C. 1396s, the committee is mandated to establish and periodically
review and, as appropriate, revise the list of vaccines for
administration to vaccine-eligible children through the Vaccines for
Children (VFC) program, along with schedules regarding the appropriate
periodicity, dosage, and contraindications applicable to the vaccines.
Further, under provisions of the Affordable Care Act, at section 2713
of the Public Health Service Act, immunization recommendations of the
ACIP that have been adopted by the Director of the Centers for Disease
Control and Prevention must be covered by applicable health plans.
Matters To Be Discussed: The agenda will include discussions on:
2013 adult immunization schedule, 2013 child/adolescent immunization
schedule, Japanese encephalitis, rotavirus, human papillomavirus
vaccines, hepatitis B vaccine, meningococcal vaccines, influenza,
measles-mumps-rubella vaccine, pertussis and vaccine supply.
Recommendation votes are scheduled for pertussis vaccines,
meningococcal vaccines, measles-mumps-rubella vaccine, hepatitis B
vaccine, child/adolescent immunization schedule, and the adult
immunization schedule. VFC votes are scheduled for pertussis vaccines,
meningococcal vaccines, and influenza vaccine. Time will be available
for public comment.
Agenda items are subject to change as priorities dictate.
Meeting is webcast live via the World Wide Web; for instructions
and more information on ACIP please visit the ACIP web site: https://www.cdc.gov/vaccines/acip/.
Contact Person for More Information: Stephanie B. Thomas, National
Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton
Road NE., MS-A27, Atlanta, Georgia 30333, telephone 404/639-8836; Email
ACIP@CDC.GOV.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities for
both the Centers for Disease Control and Prevention and the Agency for
Toxic Substances and Disease Registry.
Dated: September 14, 2012.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2012-23390 Filed 9-21-12; 8:45 am]
BILLING CODE 4160-18-P
